Such BC tumors can easily evade attacks by the immune system by expressing Programmed death-ligand 1 (PD-L1) (64), whereby, using immune checkpoint inhibitors (ICIs) in combination with chemotherapy or other immune modulators can potentially enhance treatment efficacy by restoring T-cell function, thus, providing a therapeutically effective intervention for TNBC management (65) (Figure 3C). This evidence concerns the gene CD274 and breast cancer.